Shares of Haleon plc (NYSE:HLN – Get Free Report) have earned a consensus recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $10.95.
A number of analysts have recently issued reports on the stock. Berenberg Bank started coverage on shares of Haleon in a research note on Tuesday, August 6th. They set a “buy” rating on the stock. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, Morgan Stanley lifted their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th.
Read Our Latest Research Report on HLN
Institutional Inflows and Outflows
Haleon Stock Performance
Shares of NYSE:HLN opened at $9.72 on Friday. The business’s 50-day simple moving average is $9.95 and its 200 day simple moving average is $9.41. The company has a market cap of $44.00 billion, a P/E ratio of 28.59, a PEG ratio of 2.89 and a beta of 0.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon has a one year low of $7.89 and a one year high of $10.80.
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Stories
- Five stocks we like better than Haleon
- 5 Top Rated Dividend Stocks to Consider
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- What is a Special Dividend?
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Options Trading – Understanding Strike Price
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.